Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction

Journal of Cardiac Failure

Volumn 9, Issue 3, 2003, Pages 238-245

  Kim, Young Kwon ^f   Mankad, Sunil ^a   Kim, Song Jung ^f   Takagi, Gen ^f   Tamura, Tetsutaro ^b   Gerdes, A Martin ^b   Bishop, Sanford P ^c   Kramer, Christopher M ^d,e  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b SANFORD RESEARCH   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^f NONE

Author keywords

Angiotensin; Contractile function; Infarction; Myocytes

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; RAMIPRIL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL VOLUME; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART VENTRICLE REMODELING; MORPHOMETRICS; MUSCLE CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SHEEP;

EID: 0038613667     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2003.32     Document Type: Article

References (38)

1. McKay RG, Pfeffer MA, Pasternak RC, Markis JE, Come PC, Nakao S, et al. Left ventricular remodeling following myocardial infarction: a corollary to infarct expansion. Circulation 1986;74:693-702.
2. Anversa P, Loud AV, Levicky V, Guideri G. Left ventricular failure induced by myocardial infarction: I. myocyte hypertrophy. Am J Physiol 1985;248:H876-82.
3. Anversa P, Loud AV, Levicky V, Guideri G. Left ventricular failure induced by myocardial infarction: II. tissue morphometry. Am J Physiol 1985;248:H883-89.
4. Kramer CM, Lima JAC, Reichek N, Ferrari VA, Llaneras MR, Palmon LC, et al. Regional differences in function within noninfarcted myocardium during left ventricular remodeling. Circulation 1993;88:1279-88.
5. Melillo G, Lima JAC, Judd RM, Goldschmidt-Clermont PJ, Silverman HS. Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during postinfarct left ventricular remodeling. Circulation 1996;93:1447-58.
6. Kim Y-K, S-J Kim, Kramer CM, Yantani A, Tagaki G, Mankad S, et al. Altered excitation-contraction coupling in myocytes from remodeled myocardium after chronic myocardial infarction. J Mol Cell Cardiol 2002;34:63-73.
7. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-72.
8. St. John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moye JA, Dagenais GR, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. Circulation 1994;89:68-75.
9. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. For the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
10. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
11. Kramer CM, Ferrari VA, Rogers WJ, Theobald T, Nance ML, Axel L, et al. Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling. J Am Coll Cardiol 1996;27:211-7.
12. Capasso JM, Anversa P. Mechanical performance of spared myocytes after myocardial infarction: effects of captopril treatment. Am J Physiol 1992;263:H841-9.
13. Taylor K, Patterson RD, Smith JJ, Aronovitz MJ, Wight J, Salomon RN, et al. Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats. J Cardiovasc Pharmacol 1998;31:654-60.
14. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol 1996;27:714-9.
15. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton DM, et al. Modulation of the reninangiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure effects on left ventricular performance and neurohormonal systems. Circulation 1997;96:2385-96.
16. Mankad S, d'Amato T, Reichek N, McGregor W, Lin J, Singh D, et al. Combining angiotensin II receptor antagonism and angiotensin converting enzyme inhibition further attenuates post-infarction left ventricular remodeling. Circulation, 2001;103:2845-2850,
17. Yu C-M, Tipoe GL, Lai KW-H, Lau CP. Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 2001;38:1207-15.
18. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
19. Kramer CM, Rogers WJ, Park CS, Seibel PS, Shaffer A, Theobald TM, et al. Regional myocyte hypertrophy parallels regional myocardial dysfunction during post-infarct remodeling. J Molec Cell Cardiol 1998;30:1773-8.
20. Tamura T, Said S, Harris H, Lu W, Gerdes AM. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 2000;102:253-9.
21. Marijianowski MMH, Teeling P, Becker AE. Remodeling after myocardial infarction in humans is not associated with interstitial fibrosis of noninfarcted myocardium. J Am Coll Cardiol 1997;30:76-82.
22. Sadoshima J, Izumo S. Molecular characterization of angiotensin II induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993;73:413-24.
23. Schorb W, Booz GW, Dostal DE, Konrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat fibroblasts. Circ Res 1993;72:1245-54.
24. Raya TE, Fonken SJ, Lee RW, Daugherty S, Goldman S, Wong PC, et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens 1991;4:334-40.
25. Nishikimi T, Yamagishi H, Takeuchi K, Takeda T. An angiotensin II receptor antagonist attenuates left ventricular dilatation after myocardial infarction in the hypertensive rat. Cardiovasc Res 1995;29;856-61.
26. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-82.
27. Liu Y-H, Yang X-P, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest 1997;99:1926-35.
28. Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992;105:771-2.
29. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990;66:883-90.
30. Seyedi N, Xu XB, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70.
31. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
32. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van de Werf F, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.
33. Litwin SE, Morgan JP. Captopril enhances intracellular calcium handling β-adrenergic responsiveness of myocardium from rats with postinfarction failure. Circ Res 1992;71:797-807.
34. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim-Barker A, et al. Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy: effects on left ventricular and myocyte structure and function. Circulation 1995;92:562-78.
35. Spinale FG, Mukherjee R, Iannini JP, Whitebread S, Hebbar L, Clair MJ, et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes. Circulation 1997:96;2397-406.
36. Spinale FG, Holzgrefe HH, Walker JD, Mukherjee R, Kribbs SB, Powell JR, et al. Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function. J Cardiovasc Pharmacol 1997;30:623-31.
37. Anand IS, Liu D, Chugh SS, Prahash AJ, Gupta S, John R, et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation 1997;96:3974-84.
38. Gupta S, Prahash AH, Anand IS. Myocyte contractile function is intact in the post-infarct remodeled rat heart despite molecular alterations. Cardiovasc Res 2000;48:77-88.